dm+d
109139002
Articles
Parkinson’s disease medicines formulations for adults with swallowing difficulties
13 June 2022Guidance to help you ensure your patients with Parkinson’s Disease are able to get the most from their medicines if they develop swallowing difficulties
Safety in Lactation: Bromocriptine and other dopaminergic drugs
29 September 2021These dopaminergic drugs are used for the treatment of specific pituitary and prolactin-mediated disorders, including galactorrhoea, hyperprolactinaemia and prolactinomas. They are also used to suppress…
Safety in Lactation: Dopaminergic drugs used in Parkinsons disease
25 September 2020Although rare, Parkinson’s disease can occur in younger women of childbearing age. Dopamine receptor agonists are used either alone or as an adjunct to levodopa…
Medicine Compliance Aid Stability
CabaserPharmacia Ltd
Pharmacia Ltd
Cabaser
Tablets 1mg, 2mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Hygroscopic, packaging contains dessicant. Max 7 days in MCA.
14 October 2015
Lactation Safety Information
For Parkinson's disease
For Parkinson's disease
No
Levodopa, (as co-beneldopa or co-careldopa)
May interfere with lactation
Dopamine receptor agonist
No published evidence of safety for Parkinson’s disease
18 September 2020
For hyperprolactinaemic disorders
For hyperprolactinaemic disorders
No
Suppresses lactation
No published evidence of safety for hyperprolactinaemic disorders
18 September 2020
For lactation suppression
For lactation suppression
Caution
No published evidence of safety in breastfed infants
Suppresses lactation, although low doses may be used to reduce, and not completely stop, milk production, in which case monitor infant for cabergoline-associated side effects (hypotension, constipation, drowsiness)
18 September 2020